Notably, strategies targeting Rho family-controlled pathways, including those focusing on CDC42, have garnered attention in cancer treatment (Murphy et al., 2021), infectious diseases (Hong et al., 2013), and neurodegeneration (Aguilar et al., 2017; Barcia et al., 2012; Rong et al., 2020). This evidence concerns the gene CDC42 and infectious disease.